Bladder preserving strategies for muscle-invasive bladder cancer

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 513-518

  Merseburger, Axel S ^a   Matuschek, Ira ^a   Kuczyk, Markus A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bladder cancer; Cystectomy; Radiation; Surgery; Therapy; Transurethral resection of the bladder tumour

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; SORAFENIB; TRASTUZUMAB; TUMOR MARKER;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURGERY; CYSTECTOMY; DECISION MAKING; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MUSCLE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; TRANSURETHRAL RESECTION; BLADDER; BLADDER TUMOR; ECONOMICS; LENGTH OF STAY; MULTIMODALITY CANCER THERAPY; SMOOTH MUSCLE; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DECISION MAKING; HUMANS; LENGTH OF STAY; MUSCLE, SMOOTH; QUALITY OF LIFE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 54549127189     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830b86bd     Document Type: Review

References (35)

1. Stenzl A, Cowan NC, De Santis M, et al. Guidelines on bladder cancer-muscle-invasive and metastatic. Eur Assoc Urology 2008.
2. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62-67; discussion 67-68.
3. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24:5536-5544.
4. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40:121-127.
5. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2901-2907.
6. Moul JW. Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares. Cancer 2002; 95:211-214.
7. Waehre H, Ous S, Klevmark B, et al. A bladder cancer multiinstitutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72:3044-3051.
8. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145:45-50.
9. Brendler CB, Steinberg GD, Marshall FF, et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol 1990; 144:1137-1140; discussion 1140-1131.
10. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71:3993-4001.
11. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19:666-675.
12. Weiss C, Sauer R, Rodel C. Radiochemotherapeutic options for bladder cancer. Aktuelle Urol 2008; 39:123-129.
13. Merseburger AS, Kuczyk MA. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Curr Opin Urol 2007; 17:358-362.
14. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.
15. Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68:1072-1080.
16. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58:380-385.
17. Weiss C, Wittlinger M, Engehausen DG, et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 2008; 70:1502-1506.
18. Miyanaga N, Akaza H, Hinotsu S, et al. Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Jpn J Clin Oncol 2007; 37:852-857.
19. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-93. J Clin Oncol 1998; 16:3576-3583.
20. Blank LE, Koedooder K, van Os R, et al. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5cm in diameter. Int J Radiat Oncol Biol Phys 2007; 69:454-458.
21. Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24:2318-2324.
22. Harland SJ, Kynaston H, Grigor K, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007; 178:807-813; discussion 813.
23. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68:549-553.
24. Cooksley CD, Avritscher EB, Grossman HB, et al. Clinical model of cost of bladder cancer in the elderly. Urology 2008; 71:519-525.
25. Cardenas-Turanzas M, Cooksley C, Kamat AM, et al. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 2008 [Epub ahead of print].
26. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol 2008; 86:217-223.
27. Dunscombe P, Roberts G, Walker J. The cost of radiotherapy as a function of facility size and hours of operation. Br J Radiol 1999; 72:598-603.
28. Racioppi M, Volpe A, Falabella R, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl 2007; 79:111-117.
29. Cooke PW, Dunn JA, Latief T, et al. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur Urol 2000; 38:279-286.
30. Ali-El-Dein B. Oncological outcome after radical cystectomy and orthotopic bladder substitution in women. Eur J Surg Oncol 2008 [Epub ahead of print].
31. Dhar NB, Klein EA, Reuther AM, et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008; 179:873-878; discussion 878.
32. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999; 162:77-81.
33. Hashine K, Miura N, Numata K, et al. Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Urol 2008; 15:403-406.
34. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62:309-317.
35. Brunner A, Verdorfer I, Prelog M, et al. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers. Pathobiology 2008; 75:25-33.